As students across the nation return to classrooms, a persistent shortage of Adderall, widely prescribed for Attention-Deficit/Hyperactivity Disorder (ADHD), exacerbates parental concerns. The deficit, beginning last October, persists due to manufacturing delays as demand soared during the pandemic.
The U.S. Food and Drug Administration (FDA) cites these lags for the current predicament, while acknowledging that annual production limits are set for ADHD medicines, which are classified as controlled substances. This categorization has prompted growing demands for the FDA and the U.S. Drug Enforcement Administration to revise these constraints.
Doctors emphasize the drug’s significance, remarking that it can substantially influence a child’s academic attendance and output. With millions diagnosed with ADHD, and an increasing number relying on Adderall for focus, alternatives are being sought. However, drugs like Ritalin and even generic brands face shortages.
Doctors recommend other available medications like Vyvanse, Mydayis, and Concerta as potential interim substitutes. While there have been concerns about Adderall misuse among teens, experts clarify that the current shortage mainly stems from manufacturing challenges, not misuse.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to [email protected].